## Index

Abbott Laboratories
- lopinavir, 31
  - pravafenone, 161
  - rimevir (RTV), 4, 30
Absorption, influential factors, 197, 256, 258, 282
Absorption, distribution, metabolism, and excretion (ADME) studies, 202, 314
Aceclofenac, 192
Acetonitrile, 52, 96, 186-188, 239
Acetophenone, 285
Acetylation, 170
Acetylcholine (ACh), 251
Acetylcholinesterase (AchE) functions of, 251-252, 257 inhibitors, 253, 258
Acetyl groups, 52
Active pharmaceutical ingredient (API), 22, 81-82, 93, 296, 302
Acute myelogenous leukemia (AML), 47, 50
Acylation, in syntheses process, 152, 183, 186, 188, 198, 260, 284, 317, 323-324
Acyl groups, 214
Acvacia. See Tadalafil
Adderall. See Amphetamine
ADMET profile, 75
Adrenergic receptor blocking agent, 330
Adrulin. See Fluorouracil
Advanced renal cell carcinoma, sorafenib treatment, 73-84
Adverse effects. See specific drugs
Afimoxifene
  - characterized, 311
  - chemical structure, 311
Agenerase. See Amprenavir
AIDS (acquired immunodeficiency syndrome), 29. See also HIV/AIDS
Albumin, 256
Aldehydes, 25, 93, 100, 102, 149-150, 265, 268, 318, 322, 333
Aldol reaction, 152
Aldols, 259
Aliskiren
  - background, 141-144
  - chemical structure, 141
  - drug metabolism, 146-147
  - efficacy, 147-148
  - pharmacokinetics, 146-147
  - pharmacology, 144-145
  - safety considerations, 147-148
  - structure-activity relationship, 145-146
  - syntheses, 148-156
Alkylating agents, 99
Alkyls, 105, 107, 152-153, 254, 287
Allosteric potentiating ligand (APL), 252
ALLY (Aliskiren Left Ventricular Assessment of Hypertrophy), 148
ALOFT (Aliskiren Observation of Heart Failure Treatment), 148
Alogliptin
  - characterized, 126
  - chemical structure, 126
Alzheimer's disease (AD)
  - cholinesterase inhibitors treatments, 249-271 overview of, 250 pathophysiology, 251 severity of, 258
Ambrisentan
  - characterized, 214-215
  - chemical structure, 207
  - synthesis of, 219-221
American Cancer Society, 111
American College of Clinical Oncology, 118
American Diabetes Association (ADA), 129
Ames test, 187
Amidation, 92-95
Amide(s)
  characterized, 25, 92, 214, 253-254, 300, 321
  coupling, 94
  groups, 214
Amionation, 25, 118, 232, 237, 244, 262, 265, 267
Amines, 11, 79, 234, 255, 268-270
Amino acids, 12, 108, 130-131, 142
Aminoalkyl groups, 179-180
Amino groups, 154, 179, 255
Aminoisoxazole, 217
Aminomethylation, 238
Amiodarone, 162-163
Amphetamine
  characterized, 293
  chemical structure, 292
Amprenavir, 31
Amyloid precursor protein (APP), 250
Anccrviroc
  characterized, 18
  chemical structure, 19
Anemia, 51
Angiogenesis, 75-76, 87, 102, 111, 114
Angiotensin-converting enzyme (ACE)
  functions of, 141-142
  inhibitors, 147-148
Angiotensin II
  receptor (AT1 receptor), 142, 144
  receptor blockers (ARBs), 141, 144, 147
Angiotensinogen, 142, 148
Anhydrides, 93, 107, 170
Anilines, 115-116, 186, 235
Annulation, 240
Anthraquinine therapy, 64, 70
Anti-angiogenic agents, 89, 97
Antiarrhythmic drugs, 160-163
Antibiotics, 176, 213
Anticoagulant therapy, 160, 163, 191-192
Antidiuretic hormone (ADH), 175, 177
Antihypertensives. See Aliskiren
Antileukemics, See Decitabine
Antimetabolites, 57, 61
Antiretroviral drugs, 5, 12, 29
Apixaban, 203-204
Aplaviroc, 18-19
Apolipoprotein-E4, 258
Apomorphine, 282
Apoptosis, 47, 101-102
Aprepitant
  background, 275-279
  chemical structure, 275
discovery of, 278
drug metabolism, 282
efficacy, 282-283
pharmacokinetics, 282
pharmacology
  in vitro, 279-280
  in vivo, 280-282
  safety considerations, 282-283
structure-activity relationships (SAR), 279-282, 289
synthesis, 283-289
Aptivus. See Tipranavir
Arachidonic acid, 329
Arginine vasopressin (AVP), 175-179
Aricept. See Donepezil
Armodafinil
  background to, 291-293
  characterized, 303
  chemical structure, 291
  drug metabolism, 294-295
  efficacy, 295-296, 303
  pharmacokinetics, 294-295
  pharmacology, 293-294
  safety considerations, 295-296
  synthesis, asymmetric, 299-303
Arndt-Eistert homologation, 130
Aromatics, 214
Aroyl groups, 53
ARTEMIS study, 34
Arteriovenous (AV) shunt model, 196
Arylation, 220
4-Aryl-2,4-diketobutanoic acid/1,3-Diketo
  acids (DKAs), 6-8, 12
Aryl groups, 195, 213, 234, 240
Aryls, 321, 324
Ascend Therapeutics, afimoxifene, 311
Aspartate, 78
ASPIRE HIGHER trials, 148
Astellas Pharmaceuticals, 165, 187-188
Asthma, 275
AstraZeneca
  cediranib, 120
  esomeprazole, 301
  fulvestrant, 311-313
  gefitinib, 74, 113
  omeprazole, 301
  tamoxifen, 311-314
  vandetanib, 120
Asymmetric aliphic alkylation (AAA), 268
Atazanavir, 31
Atorvastatin, 146-147
ATP binding site, 73-74
Atrasentan, 221
Index

Atrial Arrhythmia Conversion Trials (ACT), 165
Atrial Fibrillation (AF), vernakalant treatment, 159-171
Attention-deficit hyperactivity disorder (ADHD), 292
Avastin, bevacizumab, 89
Avecia Pharma, 264
Azacitidine
characterized, 49
chemical structure, 48
Azides, 283
Backbone binding concept, 30, 32, 41
Base pairs, 18
BASF, 214
BASF/Gilead/GSK, ambrisentan, 207
Bax protein, 101
Bayer, sorafenib, 88
Bayer HealthCare, 193
Bayer/Johnson & Johnson, rivaroxaban, 191-204
BAY 59-7939. See Rivaroxaban
Bazedoxifene
characterized, 311-312
chemical structure, 312
B-cells, pancreatic, 127
BCR-ABL kinase, 75
BENCHMRK clinical trials, 10
Benazepril, 179
Benazeprilene, 231, 233-240, 242
Benazapine, 183-185
Benzyloxyl, 298-299
Benzyloxyl group, 278
Benzoazepines, 179
Benzoazepines, 234
Benzoethiophenes, 312-318, 322-324
Benzoylation, 10
Benzylation, 276
Benzylation, 260-261, 283
Benzyl groups, 253-254, 270, 276, 284
Beroprost, 210
β-blockers, 160-161
Bevacizumab, 89
Biomimetics process synthesis, 265-266
Biotransformation, impact of, 61-62, 294-295
Bis-THF ligand, 34-41
Blanc chloromethylation, 218
Blood-brain barrier, 59, 257
Blood clots, 191
Blood pressure, 141-142. See also Hypertension
Boehringer Ingelheim
linagliptin, 126
tipranavir, 31
Bones
bone loss, 310
bone mineral density (BMD), 314-315
fractures, 310, 314
osteoporosis, 309-311, 313-315
Bone marrow, 47, 90, 99
Bortezomib
background, 99-101
chemical structure, 99
drug metabolism, 104
efficacy, 104-105
pharmacokinetics, 104
pharmacology, 101-102
safety considerations, 104-105
structure-activity relationship, 102-103
syntheses, 105-109
Bosentan
characterized, 212-215, 219
chemical structure, 207
synthesis of, 215-217
B-Raf, 76-77
Brain
Alzheimer’s disease (AD), 250-271
cerebral edema, 176
forebrain, 255
hippocampus, 252
medulla bloodflow, 177
neocortex, 252
neurochemistry, influential factors, 294
tissue, 59
Breast cancer, 49, 59-60, 64, 70, 76-77, 89, 91, 310-315
Bristol-Myers Squibb
apixaban, 203
atazanavir, 31
dasetinib, 74-75, 112
efavirenz, 4
saxagliptin, 126
Bromination, 148, 187, 200, 265
Bronchitis, chronic, 226
Bupropion
characterized, 229
chemical structure, 228
Butyrylcholine esterase (BuChE), 251, 254
14C-labeled rivaroxaban, 202-203
Caco-2, 104
Calcium channel antagonists, 209
blockers, 160-161
Calpain, 100
Cancer treatment, see specific types of cancers
   angiogenesis inhibitor, 87-97
   DNA methyltransferase inhibitor, 47-54
   multikinase inhibitor, 73-84
   oral chemotherapy agent, 57-70
   proteasome inhibitor, 99-109
   VEGFR tyrosine kinase inhibitors, 111-121
Capecitabine
   background, 57-60
   chemical structure, 57, 61, 66
   efficacy, 63-64
   pharmacokinetics, 63-64
   pharmacology, 60-62
   structure-activity relationship, 62-63
   syntheses, 64-70
Capillary diseases, 208
Carbamate, 62-63, 93, 201, 255, 262, 264
Carbamyl groups, 254-255, 257
Carbamoylmethyl groups, 179
Carbodiimide, 93
Carbon dioxide, 94-95
Carbon-nitrogen bond, 179
Carbonyldimidazole (CDI), 79-80, 83, 93-94, 198-201
Carbonyls, 254
Carbohydrate therapy, 89
Carboxamides, 146
Carboxylesterase, 61-63
Carcinogenesis, 101. See also Cancer
treatment; specific types of cancers
Cardiome Pharmaceuticals, vernakalant, 159-171
Cardiovascular disease
   arrhythmia, 159-160
   congestive heart failure (CHF), 175-176
   coronary heart disease (CHD), 315
   coronary occlusions, 164
   heart failure, 147-148, 165, 182, 189
   hypertension, 125, 191, 221, 330
   mortality risk, 160
   risk of, 125
   treatments
      aliskerin, 141-156
      conivaptan, 175-189
      endothelin antagonists, 207-221
      rivaroxaban, 191-204
      vernakalant, 159-171
Cardioversion, 161
Carfilzomib
   characterized, 100
   chemical structure, 101
Carmustine, 59-60
Catalysis, 152, 321
Cathepsins
   B, 100
   D, 142
   G, 102
Catheterization, 208, 210
CCR5 antagonist for treatment of HIV, maraviroc, 17-85
CD4 cells, 17, 34
CDK1/cyclin B, 76
CDK1, ormeloxifene, 311
Cediranib, 120
Celgene, azacitidine, 48
Celgene/Novartis, folicin, 292
Centers for Disease Control and Prevention (CDC), 3
Central nervous system
diseases
   Alzheimer’s disease, 249-271
   narcolepsy, 292-293, 303
   postchemotherapy emesis, 275-289
   Foot Tap test, 281
   stimulants, see Armodafinil
Central vein catheters, 210
Centron. See Ormeloxifene
CEP-18770, 100
Cephalon, armodafinil, 291-303
Cephalon-Novasep, 300, 302
Cerebrospinal fluid, 59
C-15, 331-332, 334, 336
cGMP, 211
Champix. See Varenicline
Chantix. See Varenicline
Chemical waste disposal, 95
Chemokine receptors. See CCR5
Chemotherapeutic agents. See Capecitabine
Chiral auxiliaries, 38, 133-134, 153, 270, 299
Chirality, 166-169, 262
Chlorination, 81, 217
Chloromethoxadiazole, 130-131
Cholangiocarcinoma cells, 76
Cholinergic hypothesis, 251
Chromatographic studies
   flash column, 24, 331
   high-performance liquid (HPLC), 63, 68-69, 167-168, 262
   large-scale chiral, 300
   multiple, 332-333
   purification process, 185-186
   silica gel, 52, 183, 299, 331
Chronic myelogenous leukemia (CML), 75
Chronic thromboembolic pulmonary hypertension, 191
Chymotrypsin, 102
Index

Ciba-Geigy, 144
Cirrhosis, 175-176, 189
Cisplatin therapy, 282
c-KIT, 75-76, 84, 88-90
clexane, 192
Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST), 104
Clomid. See Clomiphene
Clomiphene
characterized, 311
chemical structure, 311
Clonogenicity, 49
c-met, 76
Coagulation pathways, 193
Cognex. See Tacrine
Cognitive deficits, treatment strategies, 252-253
Colon cancer, 221
Colon cancer, 60, 63, 76, 221. See also Colorectal cancer
Colorectal cancer, 59-60, 70, 89, 91, 120
Combination therapies, 5, 59, 99, 137, 213, 215
Co-morbidity, 125, 303
Conbriza. See Bazedoxifene
Concerta. See Methylphenidate
Condensation, in syntheses process, 51, 83, 91-92, 96, 185, 199-200, 216, 219, 234, 259-261, 318, 321-322
Conformational analysis, 254, 270
Congestive heart failure (CHF), 175-176
Conivaptan
background, 175-176
chemical structure, 175
drug metabolism, 181-182
efficacy, 182-183
pharmacokinetics, 181-182
pharmacology, 177-179
safety considerations, 182-183
structure-activity relationship, 179-181
syntheses, 183-189
Contraceptives, 311-312
Copper(H)
boronide, 183
chloride, 218
CORE (Continuing Outcomes Relevant to Evista) study, 314-315
Corey aldehyde benzoate (CAB), 333-335
Corey lactone, 331
Coronary heart disease (CHD), 315
Coronary occlusions, 164
Corvert. See Ibutilide
Cost-of-goods (COG), 22, 95
Coumadin, 192. See also Rivaroxaban; Warfarin
CP-96, 345, synthesis of, 275-278
CP-99,994, 278
CP-122, 721, 278
Crixivan. See Indinavir
Crystallization, in syntheses process, 10, 36, 52-54, 82, 106-107, 133, 137, 186, 220, 234-235, 237, 266, 285-286, 334, 336
CWR22 xenograft, 104
Cyanation, 264
Cyanide, 239-240, 245
Cyano groups, 268
Cyclin-dependent kinases, 73
Cyclins, 73, 101
Cyclooxygenase, 329
Cyclopeptadiene, 235-237
Cyclosporines, 146-147, 213-214
CYP systems
CYP2A6, 232
CYP2B6, 232
CYP2C9, 116, 213-214, 282
CYP2C19, 116
CYP2D6, 22, 116, 164-165, 257-258
CYP3A4, 9, 21-22, 78, 90, 116, 146, 182, 213-214, 257-258, 282
CYP450, 9, 33
functions of, 313-314
Cysteine, 102
Cystostasis, 118
Cytidine deaminase, 50, 61, 63
Cytisine, 231
Cytochrome P450, 18, 64, 90, 115-117, 164, 182, 213, 232, 282
Cytosine, 49, 68
Cytotoxic drugs, 49, 59-61
Dacogen. See Decitabine
Darunavir
background, 29-30
characterized, 214, 220-221
chemical structure, 29, 215
derivatives, 32
drug metabolism, 33
efficacy, 33-34
pharmacokinetics, 33
pharmacology, 32-33
safety considerations, 33-34
structure-activity relationship, 32
syntheses, 34-41
Darzens condensation, 219
Dasatinib
caracterized, 75
chemical structure, 74, 112
Daytrana. See Methylphenidate
Dealkylation, 90
Debenzylation, 285, 288
Deblocking, 276
Decarboxylation, 91, 96, 185, 260
Decitabine
background, 47-49
chemical structure, 47
drug metabolism, 50
efficacy, 50-51
pharmacokinetics, 50
pharmacology, 49
safety considerations, 50-51
structure-activity relationship, 49-50
syntheses, 51-54
Dehydroistaglaptin, 134, 137
Deletions, 18
Demeclomycin, 176
Demethylation, 78, 213, 262, 265, 317-319
Demethylolation, 176
5'-Deoxy-5-fluorocytidine (5'-DFCR), 61-64, 67
5'-Deoxy-5-fluorouridine (5'-DFUR), 61-63
Deoxythymidine-5'-monophosphate (dTMP), 58
Deoxyuridine-5'-monophosphate (dUMP), 58
Department of Health and Human Services (DHHS), 5, 12
Deprotection, in syntheses process, 10, 38, 54, 64, 69, 151, 217, 234, 265, 331, 336
Deprotonation, 10, 218
Destylaition, 106
Dexamethasone, 282-283
Diastereoselectivity, 149-150, 152
Diazonium, 236
Dieckman cyclization, 183
Diels-Alder reaction, 233, 236, 244
Diethyl amino sulfur trifluoride (DAST), 23-24
Digoxin, 256
Dihydroxylation, 232, 237, 244
Diltiazem, 160
Dimerization, 96
Dinitration, 238
Diketene, 142
Diuretics, 146-147, 156, 176
DNA
hypermethylation, 48
hypomethylation, 54
methylation, 48-49
methyltransferases (DNMTs), 48-49
replication, 49, 58
synthesis, 49
Docetaxel, 60
Dofetilide
caracterized, 161-162
chemical structure, 162
Donepezil
caracterized, 250
chemical structure, 249
efficacy, 258
pharmacokinetics, 256-257
safety considerations, 258
syntheses of, 259-261
Dopamine
levels, 231-232, 252, 293
transporter (DAT) proteins, 293-294
Doxifluridine, 59-60
DPP (dipeptidyl peptidase) systems
DPP-4/DPP-4 inhibitors, 125-129, 137
DPP8, 126-127
DPP9, 126-127
Dronedarne
caracterized, 161-162
chemical structure, 162
Dr. Reddy’s Laboratories, 244, 286
Drug-drug interactions (DDIs), 8, 129, 146, 182, 213, 257
Drug metabolism. See specific drugs
Dyslipidemia, 125
EDC coupling, 131-132
EDC1, 93
Edema, cerebral, 176
Efavirenz, chemical structure, 4
Efficacy studies. See specific drugs
Eisai Pharma/Pfizer, donepezil, 249
Elastase, 102
Elderly patients, 197, 250
Eli Lilly and Company, raloxifene, 309-325
Elvitegravir, 8
Embolisms, treatment of. See Rivaroxaban
Energetics. See Aprepitant
Enalkiren, 142
Enamines, 132-135, 137
Enantioselective reductions, 264-265
Enantioselective synthesis, 262, 264, 270
Enantioselectivity, 135-137, 300
Encysive/Pfizer, sitaxsentan, 207, 213
Endometriosis
endometriical cancer, 310
endometriical hyperplasia, 315
Endothelial antagonists
background, 208-209
characterized, 211-215
chemical structures, 207
structure-activity relationship, 221
treatment of pulmonary arterial hypertension (PAH), 209-211
syntheses, 215-221
Endothelin
 converting enzyme (ECE), 212
 family, 211
 receptor type A (ET\(_A\)), 212-214
 receptor type B (ET\(_B\)), 212-215
 Enfuvirtide (T20)
 characterized, 3
 chemical structure, 4
 Enolase coupling, 240
 Enoxaparin, 192, 197, 203
 Enzymatic resolution, 153. See also specific enzymes
 Epidermal growth factor (EGF), 75
 Epidermal growth factor receptor (EGFR), 75-76
 Epigenetic therapy, 47, 50
 Epimerization, 105-106, 242
 Epoprostenol sodium
 characterized, 210
 chemical structure, 210
 Epoxidation, 38, 220
 Epoxides, 39-40, 219
 Epoxomicin, 101
 ER\(_\alpha\)/ER\(_\beta\), 310, 313, 323
 ERK inhibitors, 78
 ERK1, 76
 Erlotinib
 characterized, 75
 chemical structure, 74, 113
 Erythromycin, 213
 Eosomeprazole
 characterized, 300
 chemical structure, 301
 Esterification, 336
 Estrogen
 receptors (ERs), 310, 312
 replacement therapy (ERT), 310
 ET-1, 211-212, 214-215, 221
 Ethoxethyl groups, 336
 European Medicines Agency (EMEA)
 approvals, 144, 148
 Evista. SeeRaloxifene hydrochloride
 Exelon. See Rivastigmine
 Extracellular fluid (ECF) volume, significance of, 176
 Extravasation, 281
 Eyes. See Glaucoma
 Fablyn. See Lasofoxifene
 Factor Xa
 characterized, 193
 inhibitors, 191-204
 Falithrom. See Phenprocoumon; Rivaroxaban
 Fareston. See Toremifene
 Faslodex. See Fulvestrant
 Female health issues
 breast cancer, 49, 59-60, 64, 70, 76-77, 89, 91, 310-315
 contraceptives, 311-312
 endometrial cancer, 310
 endometrial hyperplasia, 315
 estrogen replacement therapy (ERT), 310
 menopause, 309-310
 osteoporosis, 309-311, 313-315
 ovarian cancer, 76, 315
 uterine cancer, 315
 Fetal liver tyrosine kinase receptor 3 (Flt3), 76, 88-89
 Fibroblast growth factor receptor (FGFR), 89, 114
 Fiesseleman thiophene synthesis, 217
 First-generation process synthesis, 188
 Flecainide
 characterized, 162
 chemical structure, 161
 Flolan. See Epoprostenol sodium
 Floxuridine, 59-60
 Fluid-retentive diseases, 189
 Fluorination chemistry, 26
 Fluorine, 22, 66, 69, 323
 Fluorine-18, 68
 5-Fluorouracil (5-FU), 58-59, 61, 63-64, 70, 89
 Fluorouracil, 61-62, 65
 Fluorocytosine, 65-66
 5-Fluoro-2'-deoxyuridine monophosphate
 (FdUMP), 59
 5-Fluorouracil, 91
 5-Fluorouracil, 91, 96-97
 Fluorouracil, 60
 Focalin. See Methylphenidate, 292
 Food and Drug Administration (FDA), 5, 8, 12,
 30, 48, 57, 59-60, 70, 75, 88-89, 99,
 112, 125, 144, 161, 165, 171, 176, 182,
 189, 193, 231-233, 250, 292, 311, 330
 Foot syndrome, 64
 Foot Tap test, 281
 Formylation, 96
 Fortovase. See Saquinavir
 Fosaprepitant
 characterized, 282, 279
 synthesis, 283-289
FR15906, 143
Friedel-Crafts acylation, 52, 260, 323-324
FUdR. See Flouxuridine
Fujisawa, 165
Fulvestrant
characterized, 311-314
chemical structure, 312
Furosemide, 146-147, 176, 256
Furtulon. See Dofluridine
Fusion inhibitors, 3
Fuzenon. See Enfuvirtide (T20)

Qalantamine
characterized, 250, 252-253
chemical structure, 249
discovery of, 255-256
efficacy, 258-259
pharmacokinetics, 257-258
safety considerations, 258-259
syntheses of
asymmetrical, 268-271
racemic, 265-268
Galvus. See Vildagliptin
γ-Aminobutyric acid (GABA), 252, 293
Gastric cancer, 59
Gastrointestinal stromal cell tumors (GIST),
75, 88, 90, 97
Gefitinib
characterized, 75
chemical structure, 74, 113
Gene encoding, 211
Gilead Sciences, tenofovir, 4
Glaucoma
characterized, 329
latanoprost treatment, 330-337
lower intraocular pressure (IOP), 329-330
GlaxoSmithKline
amprenavir, 31
bupropion, 228-229
clinical candidates, 278-279
lapatinib, 113
pazopanib, 111-120
Gleevec. See Imatinib
Glimepiride, 130
Glioblastoma, 89
Glipizide, 127, 130
Glucagon-like peptide 1 (GLP-1), 125-127, 129
Glucocorticoids, 99, 105
Glucose-dependent insulinoitropic polypeptide
(GLP), 125-126, 129
Glucuronidation, 8, 115, 215
Glucuronides, 314
Glutamate, 78
Glyburide, 129
Glycidol, 199
Glycosaminoglycans, 191
Glycosidation, 64, 66
Glycosylation, 52-53, 69
G-protein coupled receptors (GPCRs), 17, 294
Granisetron, 282
Grignard methodology, 321
GR-73632, 281
GR-205,171, 278
GTX Inc., toremifene, 311

Half-life. See specific drugs
Halogenation, 236
Halolactonization reaction, 154-155
Hand syndrome, 64
Heart, see Cardiovascular diseases
anatomy of, 160
-lung transplants, 210
Heck cyclization, 268
HEK-293 cells, 76
Hepatin treatment, 191
Hepatitis C virus (HCV), 6
Hepatocellular carcinoma (HCC)
characterized, 76
sorafenib treatment, 79, 84
sunitinib treatment, 89
Hepatotoxicity, 213
hERG pharmacology, 18-19, 21
HER2/neu, 76
Heterocyclic compounds, 20
Highly active antiretroviral therapies
(HAART), 3-4, 17-18, 30-31
High-performance liquid chromatography
(HPLC), 63, 68-69, 167-168, 262
High-pressure aminolysis, 151
High-throughput screening (HTS), 78, 194, 253
Hilbert-Johnson procedure, 52
HIV
drug-resistant, 29-41
infection, 209
integrase strand transfer inhibitors, DKA
class of, 12
protease (HIV-PR), 30
HIV/AIDS
characterized, 17-18
treatments, see Maraviroc; Raltegravir
HIV-1 inhibitors
integrase, raltegravir, 3-13
protease, darunavir, 29-41
Hoffmann-La Roche
capcitabine, 64, 67
saquinavir, 30
Homophenylalanine, 126-127
Hormone replacement therapy (HRT), 315
Human genome, 211
Human insulin receptor, 76
Human serum albumin, 63-64
Human umbilical cord endothelial cells (HUVEC), 113-114, 116-117
Hydrazine, 131
Hydrides, 266
Hydrochlorothiazide (HCT), 144, 147
Hydrogen bonds, 78, 214, 254
Hydrogenation, in syntheses process, 22, 38-40, 131-133, 135-137, 168, 186-187, 198, 238-239, 242-244, 259-261, 284, 336
Hydrogenolysis, 10, 133-134, 170, 232, 262, 285
Hydrolysis, in syntheses process, 33, 52, 63, 65-67, 91, 96, 130, 133, 164, 170, 185, 197, 219, 243, 257, 260, 266-267, 279, 332, 334
Hydroxylation, 33
Hydroxyl groups, 8, 10, 255, 270, 324
Hyperglycemia, 125
Hypertension, see Pulmonary arterial hypertension (PAH)
aliskerin treatment, 141-156
characterized, 125, 191, 221
ocular, 330
Hypoglycemia, 125-126, 130
Hypokatremia
characterized, 175-176, 182-183, 189
conivaptin treatment, 175-189
symptoms of, 176
Hypoxia-induced factor (HIF), 89
Ibutidine
characterized, 161-162
chemical structure, 162
ICHEME Astra-Zeneca Award, 137
IGFR1, 76
Iloprost
characterized, 211
chemical structure, 210
Imatinib
characterized, 88, 90
chemical structure, 74, 88, 112
Imidazobenzepazines, 180, 183, 185-187, 189
Imidazole, 83, 180, 185
Imidazolides, 93, 95
Imidazolidinone, 269-270
Imidazolinone, 198
Imines, 93, 264, 269-270
Immunomodulatory therapies, 88
Indanones, 254, 260
Indazoles, 116, 118
Indinavir, 31
Indolimone, 89
Infections, 210
Infectious diseases, HIV treatments
CCRS5 antagonists, 17-27
HIV-1 integrase inhibitor, 3-13
HIV-1 protease inhibitor, 29-42
Insulin, 129, 163
Integrate, 30
Interferon-α (INF-α), 88
Interleukin-1 (IL-1), 88
Intestinal cancer, 91
Ion channels
blockers, 164
functions of, 19, 163
Ionic liquids (IL), 324
Iressa. See Gefitinib
Islet B-cells, 126-127
Isoenzymes, 257
Isodinolimone, 194
Isodolone, 254
Isozymes, 116-117
Istebul. See Tamoxifen
Janssen. See Rivaroxaban; Warfarin
Janumet, 137
Januvia. See Sitagliptin
Japan Tobacco/Agoouron/Pfizer, nelfinavir, 31
Johnson and Johnson
concerta, 292
galantamine, 249
Joint United Nations Programme, HIV/AIDS, 3, 18
Jurkat cells, 76
Kabi-Pharmacia AB, latanoprost, 330, 332
Kaletra. See Lopinavir
Ketoconazole, 146-147, 257
K562 leukemia cells, 76
Kidney(s), see Renal cell carcinoma (RCC)
cancer, 113, 120
disease, 147
Knoll, 214
Knot pyrrole synthesis, 91, 95
Korea Institute of Radiological and Medical Sciences, 69
K-Ras, 77
Kumada coupling, 153
Kv1.5 blockers, 163-164
Kynapid. See Vernakalant
Kyphosis, 310

Lactacyclin
characterized, 100
chemical structure, 101

Lactam cyclization, 239

Lactimization, 240

Lafora Laboratories, modafinil, 292
Lapatinib, 113
Large-scale synthesis, 131-132

Lasoxifene
characterized, 311
chemical structure, 312

Latanoprost
chemical structure, 329
syntheses
Kabi-Pharmacia commercial process, 332-334
medicinal chemistry, 331-333
Pfizer commercial process, 333-337

Le Chatelier’s principle, 237
Leo LäkemedelAB, 228
Letairis. See Ambrisentan

Leukemia
acute myelogenous leukemia (AML), 47, 50
chronic myelogenous leukemia (CML), 75
K562 cells, 76
MEC2 cells, 76

Leucovorin, 59, 64
Leu-Val bond, 142

Lewis acid-catalyzed synthesis, 36-37, 105, 239, 324

Linagliptin
characterized, 126
chemical structure, 126

Linezolid
characterized, 201
chemical structure, 198, 201

Lithium chloride (LiCl), 105-106
Lithium hexamethyldisilazane (LiHMDS), 106

Liver, see Hepatocellular carcinoma;
Hepatotoxicity
drug metabolism and, 50, 104
esterase, 62
enzyme abnormalities, 213-214
functions of, 61-62
microsomes, 64
toxicity, 6
Loop diuretics, 176
Lopinavir, 31
Losartan, 147-148

Lovenox, 192
L-Selectride, 266, 270, 284, 287, 332
L-733,060, 278
Lung cancer, 49, 91, 226. See also Heart-lung transplant
Lymphoma, 105
Lymphopenia, 105
Lysophosphatidylcholine, 108

Macrophages, 18
Magnus synthesis, 267
Mainteinance wakefulness test (MWT), 295-296
Malic acid, 170
Mantle cell lymphoma, 105
MAPK pathway, 76
Maraviroc (MVC)
background, 17-19
chemical structure, 4, 18
pharmacokinetics, 21-22
safety considerations, 21-22
structure-activity relationship, 19-21, 25
syntheses, 22-27
Marcoumar. See Phenprocoumon; Rivaroxaban
Maropen. See Rivaroxaban; Warfarin
Masamune-Roush reaction, 334
Mass spectrometric studies, 237
Mastalgia, cyclical, 311
Mayo Clinic studies, 64
MDA-MB-231 cell lines, 49, 76
MEC2 leukemia cells, 76
Medicinal chemistry synthesis, 151-152, 215, 276, 289, 330-332
MEK inhibitors, 78
MEK-1, 76
Melanoma, 76
Melphalan, 99, 114
Memantine, 250
Memory impairment, 252-253
Menopause, 309-310
Mephalan, 105
Merck & Co., Inc.
apreptan, 275-276, 278-279, 282, 285-288
clinical candidates, 279
indinavir, 31
raltegravir, 3-13
sitagliptin, 131-132
vernakalant, 165, 171
Mesitylation, 155
Metabolic disorders, sitagliptin treatment, 125-137
Metabolism, 322
Metformin, 129-130
Methamphetamine (METH), 292, 294
Methadone, 242
Methotrexate, 59
Methoxy groups, 145-146, 255
Methylation, 10, 48-49, 115, 118, 270
Methyl groups, 48, 78, 116, 155, 195, 283-284
Methylphenidate, chemical structure, 292
Metoprolol, 160
MG132, 100, 102-103
MG262, 100, 102-103
Michael addition, 265, 270
Michael addition-elimination, 319
Michaelis-Menten constant $K_m$, 147
Michael reaction, 266
Microdialysis, 293
Milfurol. See Carmofur
Migraines, 275
Millenium discovery synthesis, 105, 108
Milophene. See Cloniphene
Miotin, 254
Mitsunobu reaction, 131-132, 199, 268
Modafinil
characterized, 292, 303
chemical structure, 292
pharmacokinetics, 294-295
pharmacology, 293-294
synthesis
enantiomers of, 299-303
overview of, 296-299
therapies, 293
Modified Kagan method, 300-301
Modiodal. See Modafinil
Monoclonal antibodies, 89
MORE (Multiple Outcomes of Raloxifene Evaluation) study, 314-315
Morphine, 282
Morpholin-3-one, 195, 202
Morpholine, 278, 287
Morpholinone, 283-284, 288
Mosher ester analysis, 35
Mozavaptan hydrochloride
characterized, 176, 178-179
chemical structure, 177
structure-activity relationships, 180-181
Multaq. See Dronedarone
Multidrug-resistant HIV
HIV-1 strains, 12
protease inhibitor treatment, 29-42
Multiple myeloma (MM), 99, 114
Mycelodysplastic syndrome (MDS), 47-50, 54
Myelosuppression, 51, 104
Myocardial infarction, 175
nAChRs, Alzheimer's disease
$\alpha_4$B2, 231-232
functions of, 231
impact of, 252
Narcolepsy, armodafinil treatment, 291-293, 303
Narwedine, 265-267, 270
Nefedipine, 209
Nelfinavir, 31
Nephrotoxicity, 176
Neurochemistry, 294
Neuropathy
diabetic, 125
impact of, 104-105
optic, 329
Neutropenia, 51, 105
Nexavar. See Sorafenib
Nexium. See Esomeprazole
NF-$\kappa$B, 101
Nicorette. See Nicotine; Tobacco-related diseases
Nicotine
addiction to, 226-227
characterized, 228-229
chemical structure, 228
Polacrilix, 228
replacement therapy (NRT), 228-229
Nilotinib
characterized, 75
chemical structure, 74, 112
Nippon Roche Research Center, 64
Nitrogens, 254
Nitration, 234-235, 243
Nitric oxide, 209
Nitrile groups, 185
Nitro groups, 118, 186
NK1 receptor, 275, 278-280, 282
Node synthesis, 270
Nolvadex. See Tamoxifen
Non-small-cell lung cancer (NSCLC), 75-76, 89, 100-101
Nonnucleotide reverse transcriptase inhibitors (NNRTIs), 3, 5, 9
Norepinephrine transporters (NET), 293
Normal sinus heart rhythm (NSR), 160-163, 165, 171
Norvir. See Ritonavir (RTV)
Novartis
aliakin, 144
imatinib, 74, 88, 112
nilotinib, 74, 112
rituximab, 292
rivastigmine, 249, 264
Novartis (continued)
  vildagliptin, 126
NSC-309132. See Zebularine
Nucleophilicity, 317, 320
Nucleotide reverse transcriptase inhibitors
  (NRTIs), 3, 9
Nucleus Basalis Magnocellularis (NMB)
  lesions, 251
Nuvigil, 292. See also Armodafinil

Obesity, 125, 148
Olefination, 283-284, 289
Olefins, 268
Omeprazole
  characterized, 300
  chemical structure, 301
Omuralide
  characterized, 100
  chemical structure, 101
Oncogenic kinases, 73
Oncology therapy, 57. See also
  Chemotherapeutic agents
Onglyza. See Saxagliptin
ONO Pharmaceuticals/GlaxoSmithKline,
  aplaviroc,
Onyx Pharmaceuticals, sorafenib, 73, 75
Opora. See Lasofoxifene
Optimized background therapy (OBT), 9
Organ damage, hypertension-related, 141-142
Ormeloxifene
  characterized, 311-312
  chemical structure, 312
Ortho-McNeil Pharmaceutical Inc., 193
OSI/Genentech/Roche, erlotinib, 74, 113
Osmium, 236-238, 245
Osteopenia, 310
Osteoporosis, 309-311, 313-315
Otamixaban, development of, 203-204
Otsuka Pharmaceutical Co.
  moxavatran hydrochloride, 177
tolvaptan, 177
Ovarian cancer, 76, 100, 315
Oxadirazole, 11
Oxazolidinone, 198, 201, 283
Oxazotobenzazepine, 185-187
Oxidation
  asymmetrical, 300-302
  coupling, 265, 270
  Swern, 34, 38-39
  in syntheses process, 36, 78, 213, 232, 257,
Phenylalanine, 38, 40
Phenyl groups, 217-218, 253-254
Phosphate groups, 279, 288
Phosphines, 241-242
Phosphonate, 335
Phosphorylation, in synthesis process, 48-49, 73-74, 76, 90, 114, 117, 288
Phthalimide, 199
PhX3A4, 330
Physostigmine, 251-254
Physuline. See Mozavaptan hydrochloride
Picolinic acid, 81
Pioglitazone, 130
Pim1, 76
Piperazine, 127, 134
Piperazidines, 253-254, 277-279, 320, 322-325
Piperidone, 240
PKA, 76
PKB, 76
PKC, 76
Plaque, Alzheimer's disease (AD), 250
Plasma renin activity (PRA), 144
Plasma renin concentration (PRC), 144
Platelet-derived growth factor (PDGF), 87, 90
Platelet-derived growth factor receptor β (PDGFR-β), 75-76, 87, 89-90
Platinum, 336
Polyubiquitination, 101
PM-1 cells, 21
Polypeptide inhibitors, 145
Polymyxin, 197
Positron emission tomography (PET), 68, 232
Postchemotherapy emesis, aprepitant treatment, 275-289
Postprandial, 126
Postthrombotic syndrome, 191
Postural hypotension, 22
Potassium channel block, 165, 171
Pott's methodology, 130
POWER 1-3 study, 34
PR-171. See Carfilzomib
Prednisone, 99, 105
Presidential Green Chemistry Award, 137
Prezista. See Darunavir
Primoc. See Omeprazole
Prix Gailen USA Award, 137
Procainamide, 161
Prodrugs, 59-62, 288
Pronestyl. See Procainamide
Propafenone, 161-162
Propylene glycol, 266
Prostaglandins (PGs), 329-330, 333-334
Prostate cell lines, 104
Protease(s)
characterized, 100, 142
inhibitors (PIs), 3, 9, 17, 30
Proteasomes, 99-102, 104
Protein synthesis, 48. See also specific types of proteins
Proteolysis, 101
Prothrombin, 193
Prothrombinase, 193
Protocol 004, 9
Provigil, 293. See also Modafinil
Pseudomonas putida, 168
Psychomotor vigilance testing (PVT), 295-296
Pthalimide, 254
p38, 76
Pulmonary arterial hypertension (PAH)
age at onset, 208
characterized, 208
clinical classification of, 208
endothelin role in, 212
pathogenesis, 209
prognosis for, 210
symptoms, WHO functional classification of, 209, 213, 215
treatment of, 209-211
Pulmonary embolism, 191
Purification, in synthesis process, 67-69, 79, 105, 302
Purines, 57
Pyridines, 64-66, 186, 199, 243, 260-261, 264
Pyridone, 217
Pyridylmethy1 groups, 179-180
Pyrimidinedione, 216
Pyrimidines, 10, 49, 57, 59-60, 114-116, 212, 214-215, 219
Pyroles, 91-92, 95-96
Pyrrolidines, 92, 167, 169-170
Pyrrolidione, 195
QPP, 126-127
QSAR analysis, 254
QT prolongation, 18-19
Quality of life issues, 215
Quenching, 334, 336
Quinoxaline, 233-235
Quinuclidine, 277-278
Radical cyclization, 34-35, 38
Raf inhibitors, 78
Raf1, 75-78
Raloxifene hydrochloride
background, 309-313
characterized, 311
Raloxifene hydrochloride (continued)
- chemical structure, 309, 312, 316
drug metabolism, 313-314
efficacy, 314-315
mechanism of action, 313
pharmacokinetics, 313-314
safety considerations, 313-314
structure-activity relationship, 318
syntheses, 315-325
Raltegravir
- background, 3, 5
- characterized, 11
- chemical structure, 1
drug metabolism, 8-9
efficacy, 9-10
pharmacokinetics, 8-9
pharmacology, 5-6
resistance to, 12
safety, 9-10
structure-activity relationship, 6-8
syntheses, 10-13
Ramipril, 145, 147
Raney nickel, 186-188
Rasilez, 144
Rate control therapy, 160
Razadyne. See Galantamine
Recentin. See Cediranib
Receptor tyrosine kinases (RTKs), 87, 89
Recrystallization, in syntheses process, 24, 52, 106, 169-170, 186-187, 217, 243, 336
Red blood cells (RBC), 47, 50
Reductive dehalogenation, 66
Remikiren, 142
Remodulin. See Treprostinil sodium
Renal cell carcinoma (RCC)
- advanced, 97, 112-113
- characterized, 100
- pazopanib treatment, 120
- sorafenib treatment, 75-76, 79, 84
- sunitinib treatment, 88-89, 97
Renin-angiotensin system (RAS), 141-142, 144, 156
Renin inhibitor, hypertension treatment, 141-156
Repolarization, 163
Reproductive endocrinology, 309
Reproductive system
- adverse drug effects, 183, 213
- contraceptives, 311-312
Resiniferatoxin, 281
RET, 76
Retinopathy, 125
Revatio. See Sildenafil
Reverse transcriptase, 17, 30
Réyataz. See Atazanavir
Rhodium, 137, 152
Rhythm control therapy, 160
Rhythmol SR. See Propafenone
Ribosomal RNA, 48
Ritalin. See Methylphenidate
Ritonavir (RTV)
- characterized, 3, 33
- chemical structure, 4, 30
Rivaroxaban
- background, 191-193
- chemical structure, 191, 194, 196, 198, 202
drug metabolism, 196-197
efficacy, 197
pharmacokinetics, 196-197
pharmacology, 193-194
safety considerations, 197
structure-activity relationship, 194-196
synthesis, 198-203
Rivastigmine
- characterized, 251-252
- chemical structure, 249
discovery of, 254-255
efficacy, 258
pharmacokinetics, 257
safety considerations, 258
syntheses of, 262-265
Roche/Actelion, bosetan, 207, 212
Roche Laboratories, Inc.
- capetitabine, 57-70
- enfuvirtide (T20), 4
- Rosiglitazone, 129
RUTH (Raloxifene Use for the Heart) study, 314-315
Salene. See Ormeloxifene
Saline therapy, 176
Salinosporamide, 101
Samse. See Tolvaptan
Sandoz, merge with Ciba-Geigy, 144
Sanofi Aventis
- clomiphene, 311
dronedarone, 162
otamixaban, 203
Saponification, in syntheses process, 11, 24, 152, 154, 217
Saquinavir, 30
Sarafotoxins, 212
Saxagliptin
- characterized, 126
- chemical structure, 126
Index

Schering-Plough
ancriviroc, 19
vircriviroc, 19
Schöllkopf’s bis-lactim methodology, 130
Schotten-Bauman conditions, 22
Seebach alkylation, 34-35
Selective estrogen receptor modulator (SERM).
  See Raloxifene hydrochloride
Selective receptor modulators (SERMs),
  pharmacology, 312-313
Selzentry. See Maraviroc (MVC)
Senile plaque, 250
Sepsis, 210
Serophene. See Clomiphene
Serotonin (5-HT), 252, 282-283, 293
Sevista. See Ormetofloxacin
Sharpless epoxidation, 38
Sharpless/Kagan system, 300
Shire
  amphetamine, 292
  methylphenidate, 292
Sildenafil
  characterized, 213-215
  chemical structure, 211
Simvastatin, 213
Sinithrome. See Acenocoumarol; Rivaroxaban
Sintror. See Acenocoumarol
Sitagliptin
  background, 125-126
  chemical structure, 125
  drug metabolism, 128-129
  efficacy, 129-130
  pharmacokinetics, 128-129
  pharmacology, 126-127
  safety considerations, 129-130
  structure-activity relationships, 127-128
  syntheses, 130-137
Sitaxsentan
  characterized, 213-214, 219
  chemical structure, 207
  synthesis of, 217-219
Sleep disorder studies, 293, 295-296
Smoking cessation, varenicline treatment, 227-245
SNAR
  coupling, 319-320
  reaction, 216-217, 240
Sodium-potassium channel blockers, 163
Sorafenib
  characterized, 75
  chemical structure, 88
Speedel/Novartis, aliskerin, 141-156
  (S)-phenylglycinamide chiral auxiliary (PGA),
    133-134
Sprycel. See Dasatinib
Sre kinase, 114
SR43845, 143
STAR (Study of Tamoxifen and Raloxifene) trial, 315
STARTMRK study, 10
Statin, 142
Stemman’s procedure, 262
Stem cells, 47, 84, 88
Stille methodology, 321
S treptomycetes lacticystinaeus, 100
Stress response, 101
Stroke, 125
Structure-activity relationship (SAR). See specific drugs
Study of Uncontrolled Multiple Myeloma
  Managed with Proteasome Inhibition Therapy (SUMMIT), 99, 104-105
Substance P, 275
Sugar protecting groups, 53
Sulfation, 115
Sulfanamides, 116, 212-213, 217-219
Sulfones, 298-299
Sulfur dioxide, 218
Sunitinib
  background, 87-89
  characterized, 75, 93
  chemical structure, 74, 87, 90, 92
  discovery and development of, 89-91
  syntheses
    discovery route, 91-92
    process route, 92-97
Sustiva. See Efavirenz
Sutent. See Sunitinib
Suzuki coupling, 267, 324
Suzuki-Miyaura coupling, 322
Swern oxidation, 34, 38-39
Syndrome of inappropriate antidiuretic
  hormone secretion (SIADH), 175-176
Systemic sclerosis, 209
Systemic vascular leakage (SYVAL), 281
Tacrine
  characterized, 251, 253
  chemical structure, 250
Tadalafil, 211
Takeda Pharmaceutical Co., alogliptin, 126
Tambocor. See Flecainide
TamoGel. See Afimoxicifene
Tamoxifen
  characterized, 311, 313-314
Tamoxifen (continued)
chemical structure, 311
Tarceva. See Erlotinib
Tassignal. See Nilotinib
Taxane therapy, 64
Tebbie olefination, 283-284, 289
Tekturna, 144. See also Aliskerin
TEMPO oxidation, 37
Tenfovir
characterized, 3
chemical structure, 4
Terleiren, 143
Tert-butyl methyl ether (TBME), 106
Tetrahydrofuran (THF), 106, 298
Theilin. See Sitaxsentia
Thiazole, 180
Thiazolobenzodiazepines, 179-180
Thiophenes, 194, 202, 213, 217
Third-generation asymmetric synthesis, 268-269
Thomas Alva Edison Patent Award, 137
3M Pharmaceuticals, flecainide, 161
Thromine, 100, 102
Thrombotic events, treatment of, 191-204
Thrombin, 102, 193
Thrombocytopenia, 51, 104-105
Thromboembolic diseases, 193
Thrombosis, 210, 310
Thrombotic events, 191, 315
Thymidine phosphorylase, 58, 61-62
Thyroid carcinoma, 76
Tibotec Pharmaceuticals, darunavir, 29-41
Ticosyn. See Dofetilide
Timolol, 330
Tipranavir, 31
Tissue selectivity, 313
TITAN study, 34
Tobacco-related diseases, 227
Tolvaptan
characterized, 176, 178
chemical structure, 177
Toremifene
characterized, 311, 314
chemical structure, 311
Torsades de Pointes (TdP), 163
Tosylation, 183
Toxicity, 62, 89
Tracleer. See Bosentan
Transcription process, 114, 310
Transfection, 294
Transplantation
heart-lung, 210
stem cell, 47
Treprostinil sodium
characterized, 211
chemical structure, 210
Triphenylethylenes (TPEs), 311-313
Tropism, 18
Tumor(s)
cell lines, 114
5-fluorouracil treatment, 59, 70
regression, 102
solid, 59-60, 75, 88, 99
stromal, 97
suppression, 101-102
suppressor genes, 48, 50
treatment of, 61, 63, 68, 73
tumorogenesis, 88-89
Tykerb. See Lapatinib
Type 2 diabetes, 125, 137, 147
Tyramine, 270
UGT1A9, 78
Upjohn prostaglandin synthesis, 333
Uremia, 176
Uridine diphosphosphate glucuronosyl transferase
1A1 (UGT1A1), 9
Uterine cancer, 315
Valodex. See Tamoxifen
Valsartan, 144-145, 147
Valturna, 144
Vandetanib, 120
Van Rheenan procedure, 237
Vaprisol. See Contivaptan
Varenicline
chemical structure, 227
drug metabolism, 232
efficacy, 232-233
pharmacokinetics, 232
pharmacology, 231-232
safety considerations, 232-233
syntheses, 233-245
Vascular disease, 125
Vascular endothelial growth factor (VEGF)
characterized, 87, 89-90
receptor (VEGFR-1/VEGFR-2/VEGFR-3),
75-76, 84, 87-90, 112-117
tyrosine kinase inhibitors
cediranib, 120
pazopanib, 111-120
vandetanib, 120
Vasoconstriction, 212
Vasodilation, 212
Vasodilators, 209
Vasopressins, contivaptan, 175-189
<table>
<thead>
<tr>
<th>Index</th>
<th>355</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasoreactivity tests, 209</td>
<td></td>
</tr>
<tr>
<td>Velcade. See Bortezomib</td>
<td></td>
</tr>
<tr>
<td>Velcade as Initial Standard Therapy in Multiple \</td>
<td></td>
</tr>
<tr>
<td>Myeloma Assessment (VISTA), 105</td>
<td></td>
</tr>
<tr>
<td>Venous thromboembolic events (VTEs), 315</td>
<td></td>
</tr>
<tr>
<td>Venous thromboembolism, 191-192, 203, 315</td>
<td></td>
</tr>
<tr>
<td>Venotaxis. See Iloprost</td>
<td></td>
</tr>
<tr>
<td>Verapamil, 160</td>
<td></td>
</tr>
<tr>
<td>Vernakalant</td>
<td></td>
</tr>
<tr>
<td>background, 159-163</td>
<td></td>
</tr>
<tr>
<td>chemical structure, 159</td>
<td></td>
</tr>
<tr>
<td>drug metabolism, 164-165</td>
<td></td>
</tr>
<tr>
<td>efficacy, 165-166</td>
<td></td>
</tr>
<tr>
<td>pharmacokinetics, 164-165</td>
<td></td>
</tr>
<tr>
<td>pharmacology, 163</td>
<td></td>
</tr>
<tr>
<td>safety considerations, 165-166</td>
<td></td>
</tr>
<tr>
<td>structure-activity relationship, 163-164</td>
<td></td>
</tr>
<tr>
<td>synthesis, 166-171</td>
<td></td>
</tr>
<tr>
<td>VHL protein, 89</td>
<td></td>
</tr>
<tr>
<td>Vicriviroc</td>
<td></td>
</tr>
<tr>
<td>characterized, 18</td>
<td></td>
</tr>
<tr>
<td>chemical structure, 19</td>
<td></td>
</tr>
<tr>
<td>Vidaza. See Azacitidine</td>
<td></td>
</tr>
<tr>
<td>Vildagliptin, 126</td>
<td></td>
</tr>
<tr>
<td>Vinacept. See Nelfinavir</td>
<td></td>
</tr>
<tr>
<td>Viral genetic material, 5</td>
<td></td>
</tr>
<tr>
<td>Viral enzymes, 5</td>
<td></td>
</tr>
<tr>
<td>Viral replication, 12</td>
<td></td>
</tr>
<tr>
<td>Viral resistance, 17-18</td>
<td></td>
</tr>
<tr>
<td>Viread. See Tenofovir</td>
<td></td>
</tr>
<tr>
<td>Vitamin K antagonists, 191, 197</td>
<td></td>
</tr>
<tr>
<td>Viviant. See Bazedoxifene</td>
<td></td>
</tr>
<tr>
<td>Volatile reagents, 297</td>
<td></td>
</tr>
<tr>
<td>Volibris. See Ambrisentan</td>
<td></td>
</tr>
<tr>
<td>von Hippel-Landau (VHL) gene, 89</td>
<td></td>
</tr>
<tr>
<td>Vorbruggeen’s strategy, 52</td>
<td></td>
</tr>
<tr>
<td>Voutient. See Pazopanib</td>
<td></td>
</tr>
<tr>
<td>Wadsworth-Enmons reaction, 331, 334</td>
<td></td>
</tr>
<tr>
<td>Waran. See Rivaroxaban; Warfarin</td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td></td>
</tr>
<tr>
<td>characterized, 191-192, 213, 15, 232, 256</td>
<td></td>
</tr>
<tr>
<td>chemical structure, 192</td>
<td></td>
</tr>
<tr>
<td>Water retention, renal, 175</td>
<td></td>
</tr>
<tr>
<td>Weinreb amide, 321</td>
<td></td>
</tr>
<tr>
<td>White blood cells, implications of, 47, 281</td>
<td></td>
</tr>
<tr>
<td>Wittig/Grignard protocol, 233</td>
<td></td>
</tr>
<tr>
<td>Wittig reaction, 331, 336</td>
<td></td>
</tr>
<tr>
<td>Wolff-Kishner reduction, 91</td>
<td></td>
</tr>
<tr>
<td>World Health Organization (WHO), 30, 209, 213, 215, 314</td>
<td></td>
</tr>
<tr>
<td>Wurtz coupling, 218</td>
<td></td>
</tr>
<tr>
<td>Wyeth/Ligand, bazedoxifene, 311</td>
<td></td>
</tr>
<tr>
<td>Xalacom, 330</td>
<td></td>
</tr>
<tr>
<td>Xalatan, 330. See also Latanoprost</td>
<td></td>
</tr>
<tr>
<td>Xarelto. See Rivaroxaban</td>
<td></td>
</tr>
<tr>
<td>Xeloda. See Capecitabine</td>
<td></td>
</tr>
<tr>
<td>Xenografts, 63, 78, 90, 102, 104, 114</td>
<td></td>
</tr>
<tr>
<td>X4 viruses, 18</td>
<td></td>
</tr>
<tr>
<td>X-ray</td>
<td></td>
</tr>
<tr>
<td>crystallography, 32, 78, 299</td>
<td></td>
</tr>
<tr>
<td>diffraction, single-crystal, 242</td>
<td></td>
</tr>
<tr>
<td>Xylenes, 284</td>
<td></td>
</tr>
<tr>
<td>Yamanouchi Pharmaceuticals, 178, 187</td>
<td></td>
</tr>
<tr>
<td>Zactima. See Vandetanib</td>
<td></td>
</tr>
<tr>
<td>Zankyren, 142</td>
<td></td>
</tr>
<tr>
<td>Zebularine</td>
<td></td>
</tr>
<tr>
<td>characterized, 49</td>
<td></td>
</tr>
<tr>
<td>chemical structure, 48</td>
<td></td>
</tr>
<tr>
<td>Zyban. See Bupropion</td>
<td></td>
</tr>
<tr>
<td>Zyvox. See Linezolid</td>
<td></td>
</tr>
</tbody>
</table>